Baclofen in the Treatment of Alcohol Use Disorder

Last updated on March 12th, 2026 at 02:59 pm

Baclofen in the Treatment of Alcohol Use Disorder

Alcohol use disorder (AUD) is a challenging condition characterized by the inability to control alcohol consumption, leading to significant impairment or distress. Fortunately, there are various treatment options available, including pharmacotherapy. One such medication gaining attention is Baclofen.

Craving poses a significant challenge in managing patients with alcohol dependence. In experimental studies aimed at reducing craving, Baclofen stands out with a notable advantage over other pharmacological agents.

NIH clinical experience suggests that Baclofen reduces craving and alcohol consumption including in those with poor motivation. The drug causes few side effects and does not add to the intoxication effect of alcohol. Considering that Baclofen is safe in those with liver cirrhosis and reduces withdrawal symptoms due to alcohol, a controlled trial comparing it with standard treatment is required.

Alcohol use and misuse remain significant global health concerns, contributing to disability and premature death. Alcohol use disorders (AUD) encompass a spectrum of behaviors, ranging from heavy drinking to alcohol abuse and severe alcohol dependence. In India, a nationwide epidemiological study reported a prevalence of 21.4% for “current use” of alcohol, with at least 17% of users potentially dependent.

Effective management of AUD involves a combination of pharmacological and psychosocial interventions. While disulfiram serves as an aversive treatment, other pharmacological approaches are essential during alcohol withdrawal (including delirium and seizures) and for reducing craving after alcohol cessation.

Understanding Craving:

• The World Health Organization (WHO) defines craving as a strong desire or compulsion to consume a substance (whether drugs or alcohol). Craving poses a formidable barrier in the management of patients with alcohol dependence.
• Researchers continue to explore the neurobiological basis of craving, leading to various possibilities for pharmacological management-.

Baclofen for Craving Management:

• Baclofen, primarily used to reduce spasticity in neurological disorders (such as multiple sclerosis and cerebral palsy), has gained attention for its role in craving management.
• Mechanism: Baclofen acts as an agonist on metabotropic G-protein (GABAB) receptors.
• Preclinical studies demonstrate that Baclofen suppresses alcohol-stimulated dopamine release, affecting alcohol-reinforced behaviors.
• Clinical studies show reduced alcohol withdrawal symptoms when Baclofen is administered as prophylaxis or treatment-.
• Kidney elimination (85%) allows for safe use in patients with alcohol-related liver diseases.
• While Baclofen’s efficacy has been studied in several countries, systemic research specific to its use in India remains limited.

In clinical practice, caution is advised when prescribing Baclofen for craving management in patients with alcohol dependence. Always consult with a healthcare provider to tailor treatment to individual needs.

What Is Baclofen?

• Baclofen is a selective agonist of gamma-aminobutyric acid (GABA) receptors.
• Initially approved for treating muscle spasticity, it is now being evaluated for AUD treatment.

Mechanism of Action

• Baclofen’s potential mechanism of action in AUD is through the suppression of alcohol-stimulated dopamine release.
• By acting on GABA receptors, it may help reduce cravings and improve abstinence.

Clinical Evidence

• A Cochrane review analyzed 17 randomized controlled trials evaluating Baclofen for AUD treatment.
• Benefits:
  • Reduced Relapse Risk: Baclofen-treated patients had a lower risk of relapse compared to placebo (risk ratio = 0.87; absolute risk difference = 10%; number needed to treat = 10).
  • Increased Abstinent Days: Baclofen increased the number of abstinent days.
• Adverse Events:
  • Minor adverse events included dizziness, dry mouth, fatigue, paresthesias, and somnolence.
  • Overall, no significant increase in adverse events was observed.

Considerations

• Baclofen is not yet a first-line medication for AUD but can be effective for some individuals.
• If other medications are ineffective or poorly tolerated, Baclofen may be a viable option.

Remember that individual responses to medications can vary, and it’s essential to consult with a healthcare provider to determine the most suitable treatment approach for each patient. Always seek professional advice before starting any new medication. 

For more information, you can refer to theAmerican Family Physician article and theCochrane review.